Stockwatch: The commercial paradox of Ebola
This article was originally published in Scrip
Executive Summary
There are two factors that limit the ability of the Ebola virus to become a global public health tragedy: its inefficient method of transmission between humans; and its natural reservoir, which seems to be bats located in distal east Africa. These and other facets of the disease paradoxically make the Ebola virus a positive public relations opportunity for big pharmaceutical companies, but a loss-making opportunity for their small biotechnology brethren.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.